Zhaoyuan Pharma (06127) Projects H1 Net Profit Up 885%-1377%, CXO Sector Backed by Drug Export Surge

JOINN21.35%
Zhaoyuan Pharma (06127) expects first-half 2026 net profit attributable to shareholders to increase 884.9% to 1,377.4% year-over-year, according to the company's earnings guidance. The growth is supported by a record-high scale of domestic innovative drug business development exports this year, combined with a significant recovery in overseas biomedical financing, indicating improved demand both domestically and internationally.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments